{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:27:54Z","timestamp":1790659674155,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T00:00:00Z","timestamp":1696636800000},"content-version":"vor","delay-in-days":736,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007509","name":"Sociedad Espa\u00f1ola de Neumolog\u00eda y Cirug\u00eda Tor\u00e1cica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007509","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.rmed.2021.106595","type":"journal-article","created":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T22:23:04Z","timestamp":1630534984000},"page":"106595","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Efficacy of mepolizumab in usual clinical practice and characteristics of responders"],"prefix":"10.1016","volume":"187","author":[{"given":"Carlota","family":"Rodr\u00edguez-Garc\u00eda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Blanco-Aparicio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Jos\u00e9","family":"Nieto-Fontarigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagore","family":"Blanco-Cid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coral","family":"Gonzalez-Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Mosteiro-A\u00f1on","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ux\u00edo","family":"Calvo-Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Perez-De-Llano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Dolores","family":"Corbacho-Abelaira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Lourido-Cebreiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Miguel","family":"Dominguez-Juncal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Crespo-Diz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Dacal-Quintas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abel","family":"Pallares-Sanmartin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dacal-Rivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Javier","family":"Gonzalez-Barcala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmed.2021.106595_bib2","doi-asserted-by":"crossref","first-page":"101836","DOI":"10.1016\/j.pupt.2019.101836","article-title":"One year of mepolizumab. Efficacy and safety in real-life in Italy","volume":"58","author":"Bagnasco","year":"2019","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.rmed.2021.106595_bib3","doi-asserted-by":"crossref","first-page":"101946","DOI":"10.1016\/j.pupt.2020.101946","article-title":"Effectiveness of mepolizumab therapy in patients with severe eosinophilic asthma: Austrian real-life data","volume":"64","author":"Renner","year":"2020","journal-title":"Pulm. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.rmed.2021.106595_bib4","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/MAJ.0000000000000518","article-title":"Characteristics and prognosis of near-fatal asthma exacerbations","volume":"350","author":"Gonzalez-Barcala","year":"2015","journal-title":"Am. J. Med. Sci."},{"issue":"1","key":"10.1016\/j.rmed.2021.106595_bib5","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s11845-017-1633-9","article-title":"Asthma exacerbations: risk factors for hospital readmissions","volume":"187","author":"Gonzalez-Barcala","year":"2018","journal-title":"Ir. J. Med. Sci."},{"issue":"2","key":"10.1016\/j.rmed.2021.106595_bib6","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3109\/02770903.2010.539294","article-title":"Factors associated with a higher prevalence of work disability among asthmatic patients","volume":"48","author":"Gonzalez Barcala","year":"2011","journal-title":"J. Asthma"},{"issue":"5","key":"10.1016\/j.rmed.2021.106595_bib7","doi-asserted-by":"crossref","first-page":"1902420","DOI":"10.1183\/13993003.02420-2019","article-title":"Mepolizumab effectiveness and identification of super-responders in severe asthma","volume":"55","author":"Harvey","year":"2020","journal-title":"Eur. Respir. J."},{"issue":"2","key":"10.1016\/j.rmed.2021.106595_bib8","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.chest.2020.03.042","article-title":"Real-world effectiveness and the characteristics of a \"Super-Responder\" to mepolizumab in severe eosinophilic asthma","volume":"158","author":"Kavanagh","year":"2020","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.rmed.2021.106595_bib9","doi-asserted-by":"crossref","first-page":"1902345","DOI":"10.1183\/13993003.02345-2019","article-title":"Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme","volume":"55","author":"Taill\u00e9","year":"2020","journal-title":"Eur. Respir. J."},{"issue":"13","key":"10.1016\/j.rmed.2021.106595_bib10","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.rmed.2021.106595_bib11","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur. Respir. J."},{"issue":"4","key":"10.1016\/j.rmed.2021.106595_bib12","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.arbres.2019.07.003","article-title":"\u03b2 2-agonists in asthma: the strange case of Dr. Jekyll and Mr. Hyde","volume":"56","author":"Mu\u00f1oz","year":"2020","journal-title":"Arch. Bronconeumol."},{"key":"10.1016\/j.rmed.2021.106595_bib13","article-title":"Blood eosinophil count as predictor of asthma exacerbation. A meta-analysis","author":"Mallah","year":"2020","journal-title":"Pediatr. Allergy Immunol."},{"key":"10.1016\/j.rmed.2021.106595_bib14","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejim.2018.02.034","article-title":"Association between blood eosinophil count with asthma hospital readmissions","volume":"53","author":"Gonzalez-Barcala","year":"2018","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.rmed.2021.106595_bib15","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12931-015-0299-y","article-title":"Asthma characteristics and biomarkers from the Airways Disease Endotyping for Personalized Therapeutics (ADEPT) longitudinal profiling study","volume":"16","author":"Silkoff","year":"2015","journal-title":"Respir. Res."},{"key":"10.1016\/j.rmed.2021.106595_bib16","article-title":"Biologics in asthma: don't let the magic bullets sink the boat","author":"Blanco-Aparicio","year":"2020","journal-title":"Arch. Bronconeumol."},{"issue":"5","key":"10.1016\/j.rmed.2021.106595_bib17","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1080\/02770903.2020.1723623","article-title":"Mepolizumab add-on therapy in a real world cohort of patients with severe eosinophilic asthma: response rate, effectiveness, and safety","volume":"58","author":"van Toor","year":"2021","journal-title":"J. Asthma"},{"issue":"5","key":"10.1016\/j.rmed.2021.106595_bib18","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir. Med."},{"issue":"6","key":"10.1016\/j.rmed.2021.106595_bib19","doi-asserted-by":"crossref","first-page":"1801444","DOI":"10.1183\/13993003.01444-2018","article-title":"Randomised controlled trials in severe asthma: selection by phenotype or stereotype","volume":"52","author":"Brown","year":"2018","journal-title":"Eur. Respir. J."},{"issue":"13","key":"10.1016\/j.rmed.2021.106595_bib20","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"Suppl 86","key":"10.1016\/j.rmed.2021.106595_bib21","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1398-9995.2007.01620.x","article-title":"Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the world health Organization, GA(2)LEN [Global Allergy and asthma European Network] and AllerGen)","volume":"63","author":"Bousquet","year":"2008","journal-title":"Allergy"},{"key":"10.1016\/j.rmed.2021.106595_bib22","article-title":"Long-term therapy response to anti-IL-5 biologics in severe asthma-A real-life evaluation","author":"Eger","year":"2020","journal-title":"J Allergy Clin. Immunol. Pract."},{"issue":"9842","key":"10.1016\/j.rmed.2021.106595_bib23","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.rmed.2021.106595_bib24","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/cea.13601","article-title":"Real-word experience with mepolizumab: does it deliver what it has promised?","volume":"50","author":"Schleich","year":"2020","journal-title":"Clin. Exp. Allergy"},{"issue":"1","key":"10.1016\/j.rmed.2021.106595_bib25","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1034\/j.1399-3003.1999.14a06.x","article-title":"What are minimal important changes for asthma measures in a clinical trial?","volume":"14","author":"Santanello","year":"1999","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2021.106595_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2021.01.008","article-title":"The relationship between FeNO and effectiveness of mepolizumab and benralizumab in severe eosinophilic asthma","author":"Hearn","year":"2021","journal-title":"J Allergy Clin. Immunol. Pract."},{"issue":"1","key":"10.1016\/j.rmed.2021.106595_bib27","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s12890-018-0689-2","article-title":"Anti-IL-5 therapy in patients with severe eosinophilic asthma - clinical efficacy and possible criteria for treatment response","volume":"18","author":"Drick","year":"2018","journal-title":"BMC Pulm. Med."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611121003024?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611121003024?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T12:31:45Z","timestamp":1760617905000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611121003024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":26,"alternative-id":["S0954611121003024"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2021.106595","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of mepolizumab in usual clinical practice and characteristics of responders","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2021.106595","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106595"}}